Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

The program will fast-track residency and citizenship for wealthy immigrants. President Donald Trump announced that his "gold card" immigration plan has officially launched – a system the ...

The American Hospital Association, Maine Hospital Association and four safety-net hospitals have filed a federal lawsuit to halt “unlawful” changes to the 340B drug pricing program, warning the shift ...

The hospital lobby has filed a lawsuit seeking to block the federal government’s 340B Rebate Model Pilot Program, which is set to swap out safety-net providers’ longstanding upfront drug discounts for ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...

Lottery jackpots have exploded in size over the last decade. When Powerball launched in 1992, the first jackpot was $5.9 million, according to the Multi-State Lottery Association. Now, the largest ...

Edwards Lifesciences (EW) newly projected 2026 adjusted EPS guidance of $2.80-$2.95 includes to consensus figure of $2.86. The maker of products to treat advanced cardiovascular diseases also sees ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.